Eurazeo, through its Private Debt team, joined forces with Keensight Capital to support the acquisition of Inke through a unitranche credit facilty. The transaction is the 8th sponsor-led financing arranged in the Iberian Peninsula.
Set up in 1980 and based in Castellbisbal near Barcelona (Spain), Inke is the leader in micronization of complex Active Pharmaceutical Ingredients (“APIs”). The group has a specialization in inhalation APIs with a differentiated first-to-market approach. Inke combines a high regulatory expertise with close-knit relationships with major pharmaceutical companies worldwide, including in core markets such as the US, the EU and the highly regulated Japanese market.
Arnaud Maisonneuve, Managing Director, Eurazeo said:
« Inke has established itself as a leading manufacturer of complex micronized bronchodilators, demonstrating a high consistency of compliance, quality and differentiated capabilities to serve a blue-chip and global customer base. We feel confident that Inke will prosper and continue to expand its portfolio of APIs and its end-markets with the support of Keensight Capital. »
